Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Risk factors for nonadherence to warfarin: results from the IN-RANGE study.

Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, Parker CS, Price M, Metlay JP, Cohen A, Newcomb CW, Strom BL, Laskin MS, Kimmel SE.

Pharmacoepidemiol Drug Saf. 2008 Sep;17(9):853-60. doi: 10.1002/pds.1556.

2.

Can we predict daily adherence to warfarin?: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study.

Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, Parker CS, Price M, Metlay JP, Cohen A, Newcomb CW, Strom BL, Laskin MS, Kimmel SE.

Chest. 2010 Apr;137(4):883-9. doi: 10.1378/chest.09-0039. Epub 2009 Nov 10.

3.

The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study.

Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, Brensinger CM, Newcomb CW, Samaha FF, Gross R.

Arch Intern Med. 2007 Feb 12;167(3):229-35.

PMID:
17296877
4.

Nonadherence with INR monitoring and anticoagulant complications.

Witt DM, Delate T, Clark NP, Garcia DA, Hylek EM, Ageno W, Dentali F, Crowther MA.

Thromb Res. 2013 Aug;132(2):e124-30. doi: 10.1016/j.thromres.2013.06.006. Epub 2013 Jun 22.

PMID:
23800635
5.

Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study.

Parker CS, Chen Z, Price M, Gross R, Metlay JP, Christie JD, Brensinger CM, Newcomb CW, Samaha FF, Kimmel SE.

J Gen Intern Med. 2007 Sep;22(9):1254-9. Epub 2007 Jun 22.

6.

Effect of warfarin nonadherence on control of the International Normalized Ratio.

Waterman AD, Milligan PE, Bayer L, Banet GA, Gatchel SK, Gage BF.

Am J Health Syst Pharm. 2004 Jun 15;61(12):1258-64.

PMID:
15259756
7.

Health literacy and anticoagulation-related outcomes among patients taking warfarin.

Fang MC, Machtinger EL, Wang F, Schillinger D.

J Gen Intern Med. 2006 Aug;21(8):841-6.

8.

Association Between Patient-Reported Medication Adherence and Anticoagulation Control.

Sevilla-Cazes J, Finkleman BS, Chen J, Brensinger CM, Epstein AE, Streiff MB, Kimmel SE.

Am J Med. 2017 Sep;130(9):1092-1098.e2. doi: 10.1016/j.amjmed.2017.03.038. Epub 2017 Apr 26.

PMID:
28454906
9.

One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events.

Chen SY, Wu N, Gulseth M, LaMori J, Bookhart BK, Boulanger L, Fields L, Schein J.

J Manag Care Pharm. 2013 May;19(4):291-301.

10.

Effect of a warfarin adherence aid on anticoagulation control in an inner-city anticoagulation clinic population.

Nochowitz B, Shapiro NL, Nutescu EA, Cavallari LH.

Ann Pharmacother. 2009 Jul;43(7):1165-72. doi: 10.1345/aph.1L707. Epub 2009 Jun 23.

PMID:
19549747
12.

Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink.

Macedo AF, Bell J, McCarron C, Conroy R, Richardson J, Scowcroft A, Sunderland T, Rotheram N.

Thromb Res. 2015 Aug;136(2):250-60. doi: 10.1016/j.thromres.2015.06.007. Epub 2015 Jun 9.

13.

Patient attitudinal and behavioral factors associated with warfarin non-adherence at outpatient anticoagulation clinics.

Cruess DG, Localio AR, Platt AB, Brensinger CM, Christie JD, Gross R, Parker CS, Price M, Metlay JP, Cohen A, Newcomb CW, Strom BL, Kimmel SE.

Int J Behav Med. 2010 Mar;17(1):33-42. doi: 10.1007/s12529-009-9052-6.

14.

The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective.

Casciano JP, Dotiwala ZJ, Martin BC, Kwong WJ.

J Manag Care Pharm. 2013 May;19(4):302-16.

15.

Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation.

Spivey CA, Qiao Y, Liu X, Mardekian J, Parker RB, Phatak H, Claflin AB, Kachroo S, Abdulsattar Y, Chakrabarti A, Wang J.

J Manag Care Spec Pharm. 2015 Jul;21(7):596-606.

16.

Intensity of anticoagulation with warfarin and risk of adverse events in patients presenting to the emergency department.

Anthony CJ, Karim S, Ackroyd-Stolarz S, Fry A, Murphy NG, Christie R, Zed PJ.

Ann Pharmacother. 2011 Jul;45(7-8):881-7. doi: 10.1345/aph.1P670. Epub 2011 Jul 12.

PMID:
21750309
17.

Use of direct observed therapy to confirm compliance in a warfarin clinic.

Deen R.

J Patient Saf. 2011 Dec;7(4):232-3. doi: 10.1097/PTS.0b013e3182382efc.

PMID:
22064623
18.

Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study.

Clark NP, Witt DM, Delate T, Trapp M, Garcia D, Ageno W, Hylek EM, Crowther MA; Warfarin-Associated Research Projects and Other Endeavors Consortium.

Pharmacotherapy. 2008 Aug;28(8):960-7. doi: 10.1592/phco.28.8.960.

PMID:
18657012
19.

Effect of heart failure exacerbations on anticoagulation: a prospective, observational, pilot cohort study.

Ripley TL, Harrison D, Germany RE, Adamson PB.

Clin Ther. 2010 Mar;32(3):506-14. doi: 10.1016/j.clinthera.2010.03.001.

PMID:
20399987
20.

Factors affecting medication adherence and anticoagulation control in Korean patients taking warfarin.

Kim JH, Kim GS, Kim EJ, Park S, Chung N, Chu SH.

J Cardiovasc Nurs. 2011 Nov-Dec;26(6):466-74. doi: 10.1097/JCN.0b013e31820914e7.

PMID:
21912274

Supplemental Content

Support Center